Mario Delia

Bari, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 94 publications

Pre-emptive versus empirical antifungal therapy in patients with febrile neutropenia with acute leukaemia: a GIMEMA study.

Pre-emptive versus empirical antifungal therapy in patients with febrile neutropenia with acute leukaemia: a GIMEMA study.

Journal: JAC-antimicrobial resistance

Published: June 29, 2026

Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study.

Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study.

Journal: Bone marrow transplantation

Published: May 27, 2026

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Journal: Blood reviews

Published: March 18, 2026

Chimeric Antigen Receptor-T Cells Fate after Infusion: Cellular Kinetics and Molecular Monitoring.

Chimeric Antigen Receptor-T Cells Fate after Infusion: Cellular Kinetics and Molecular Monitoring.

Journal: Transplantation and cellular therapy

Published: March 16, 2026

How unfitness criteria can make a difference in treating AML patients with hypomethylating agents and venetoclax.

How unfitness criteria can make a difference in treating AML patients with hypomethylating agents and venetoclax.

Journal: British journal of haematology

Published: January 11, 2026

Correction: RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications.

Correction: RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications.

Journal: Cancer gene therapy

Published: November 03, 2025

Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?

Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?

Journal: Annals of hematology

Published: October 22, 2025

Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry.

Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry.

Journal: Open forum infectious diseases

Published: September 24, 2025

Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS-COV-2-A Report From the EPICOVIDEHA/EPIRESEHA Registry.

Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS-COV-2-A Report From the EPICOVIDEHA/EPIRESEHA Registry.

Journal: American journal of hematology

Published: July 22, 2025

Splenomegaly in de novo acute myeloid leukemia is associated with ASXL1 mutations together with a distinct clinical and gene expression profile.

Splenomegaly in de novo acute myeloid leukemia is associated with ASXL1 mutations together with a distinct clinical and gene expression profile.

Journal: Biomarker research

Published: July 03, 2025

Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study.

Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study.

Journal: Hematological oncology

Published: June 23, 2025

Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group.

Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group.

Journal: Annals of hematology

Published: May 30, 2025

Showing 1-12 of 94

Last Updated: 09/26/2026